Patient-derived organoid-immune co-cultures integrated with multi-omics reveal immunotherapy resistance mechanisms in urothelial carcinoma

References

[1] Babjuk, Marko, Maximilian Burger, Otakar Capoun, Daniel Cohen, Eva M. Compérat, José L Dominguez Escrig, Paolo Gontero, et al. 2022. “European Association of Urology Guidelines on Non-Muscle-Invasive Bladder Cancer (Ta, T1, and Carcinoma in Situ).” European Urology 81: 75–94. https://doi.org/10.1016/j.eururo.2021.08.010

[2] Witjes, J Alfred, Harman Max Bruins, Richard Cathomas, Eva M. Compérat, Nigel C. Cowan, Georgios Gakis, Virginia Hernández, et al. 2021. “European Association of Urology Guidelines on Muscle-Invasive and Metastatic Bladder Cancer: Summary of the 2020 Guidelines.” European Urology 79: 82–104. https://doi.org/10.1016/j.eururo.2020.03.055

[3] Bray, Freddie, Mathieu Laversanne, Hyuna Sung, Jacques Ferlay, Rebecca L. Siegel, Isabelle Soerjomataram, and Ahmedin Jemal. 2024. “Global Cancer Statistics 2022: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.” CA Cancer Journal of Clinicians 74: 229–263. https://doi.org/10.3322/caac.21834

[4] Shvero, Asaf, and Scott G. Hubosky. 2022. “Management of Upper Tract Urothelial Carcinoma.” Current Oncology Reports 24: 611–619. https://doi.org/10.1007/s11912-021-01179-8

[5] Foth, Mona, Nur Faezah Binti Ismail, Jeng Sum Charmaine Kung, Darren Tomlinson, Margaret A. Knowles, Pontus Eriksson, Gottfrid Sjödahl, et al. 2018. “FGFR3 Mutation Increases Bladder Tumourigenesis by Suppressing Acute Inflammation.” Journal of Pathology 246: 331–343. https://doi.org/10.1002/path.5143

[6] Jing, Weiqiang, Ganyu Wang, Zhiwei Cui, Gaozhong Xiong, Xin Jiang, Yue Li, Wushan Li, et al. 2022. “FGFR3 Destabilizes PD-L1 via NEDD4 to Control T-cell-Mediated Bladder Cancer Immune Surveillance.” Cancer Research 82: 114–129. https://doi.org/10.1158/0008-5472.Can-21-2362

[7] Rosti, Gianantonio, Fausto Castagnetti, Gabriele Gugliotta, and Michele Baccarani. 2017. “Tyrosine Kinase Inhibitors in Chronic Myeloid Leukaemia: Which, When, for Whom?” Nature Reviews Clinical Oncology 14: 141–154. https://doi.org/10.1038/nrclinonc.2016.139

[8] Chapman, Paul B., Axel Hauschild, Caroline Robert, John B. Haanen, Paolo Ascierto, James Larkin, Reinhard Dummer, et al. 2011. “Improved Survival with Vemurafenib in Melanoma With BRAF V600E Mutation.” New England Journal of Medicine 364: 2507–2516. https://doi.org/10.1056/NEJMoa1103782

[9] Ramalingam, Suresh S., James C.-H. Yang, Chee Khoon Lee, Takayasu Kurata, Dong-Wan Kim, Thomas John, Naoyuki Nogami, et al. 2018. “Osimertinib As First-Line Treatment of EGFR Mutation-Positive Advanced Non-Small-Cell Lung Cancer.” Journal of Clinical Oncology 36: 841–849. https://doi.org/10.1200/jco.2017.74.7576

[10] Loibl, Sibylle, and Luca Gianni. 2017. “HER2-Positive Breast Cancer.” The Lancet 389: 2415–2429. https://doi.org/10.1016/s0140-6736(16)32417-5

[11] Li, Roger, Joshua Linscott, James W. F. Catto, Siamak Daneshmand, Bishoy M. Faltas, Ashish M. Kamat, Joshua J. Meeks, et al. 2025. “FGFR Inhibition in Urothelial Carcinoma.” Eur. Urol. 87: 110–122. https://doi.org/10.1016/j.eururo.2024.09.012

[12] Loriot, Yohann, Nobuaki Matsubara, Se Hoon Park, Robert A. Huddart, Earle F. Burgess, Nadine Houede, Severine Banek, et al. 2023. “Erdafitinib or Chemotherapy in Advanced or Metastatic Urothelial Carcinoma.” New England Journal of Medicine 389: 1961–1971. https://doi.org/10.1056/NEJMoa2308849

[13] Robertson, A Gordon, Jaegil Kim, Hikmat Al-Ahmadie, Joaquim Bellmunt, Guangwu Guo, Andrew D. Cherniack, Toshinori Hinoue, et al. 2017. “Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer.” Cell 171: 540–556.e25. https://doi.org/10.1016/j.cell.2017.09.007

[14] Moss, Tyler J., Yuan Qi, Liu Xi, Bo Peng, Tae-Beom Kim, Nader E. Ezzedine, Maribel E. Mosqueda, et al. 2017. “Comprehensive Genomic Characterization of Upper Tract Urothelial Carcinoma.” European Urology 72: 641–649. https://doi.org/10.1016/j.eururo.2017.05.048

[15] Ouyang, Yi, Ziwei Ou, Wenlong Zhong, Jin Yang, Sha Fu, Nengtai Ouyang, Junyu Chen, et al. 2023. “FGFR3 Alterations in Bladder Cancer Stimulate Serine Synthesis to Induce Immune-Inert Macrophages That Suppress T-Cell Recruitment and Activation.” Cancer Research 83: 4030–4046. https://doi.org/10.1158/0008-5472.Can-23-1065

[16] Vlachogiannis, Georgios, Somaieh Hedayat, Alexandra Vatsiou, Yann Jamin, Javier Fernández-Mateos, Khurum Khan, Andrea Lampis, et al. 2018. “Patient-Derived Organoids Model Treatment Response of Metastatic Gastrointestinal Cancers.” Science 359: 920–926. https://doi.org/10.1126/science.aao2774

[17] Ooft, Salo N., Fleur Weeber, Krijn K. Dijkstra, Chelsea M. McLean, Sovann Kaing, Erik van Werkhoven, Luuk Schipper, et al. 2019. “Patient-Derived Organoids Can Predict Response to Chemotherapy in Metastatic Colorectal Cancer Patients.” Science Translational Medicine 11: eaay2574. https://doi.org/10.1126/scitranslmed.aay2574

[18] Tiriac, Hervé, Pascal Belleau, Dannielle D. Engle, Dennis Plenker, Astrid Deschênes, Tim D. D. Somerville, Fieke E. M. Froeling, et al. 2018. “Organoid Profiling Identifies Common Responders to Chemotherapy in Pancreatic Cancer.” Cancer Discovery 8: 1112–1129. https://doi.org/10.1158/2159-8290.Cd-18-0349

[19] Yao, Ye, Xiaoya Xu, Lifeng Yang, Ji Zhu, Juefeng Wan, Lijun Shen, Fan Xia, et al. 2020. “Patient-Derived Organoids Predict Chemoradiation Responses of Locally Advanced Rectal Cancer.” Cell Stem Cell 26: 17–26.e6. https://doi.org/10.1016/j.stem.2019.10.010

Rights & permissions

2026 The Author(s). iMeta published by John Wiley & Sons Australia, Ltd on behalf of iMeta Science.